Mesa Laboratories (NASDAQ:MLAB) Director Acquires $99,940.00 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director R Tony Tripeny bought 1,315 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average cost of $76.00 per share, with a total value of $99,940.00. Following the acquisition, the director directly owned 5,398 shares of the company’s stock, valued at approximately $410,248. This represents a 32.21% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mesa Laboratories Trading Down 3.5%

MLAB stock opened at $77.81 on Friday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.45 and a current ratio of 1.94. The company’s 50-day simple moving average is $87.39 and its 200 day simple moving average is $78.22. The company has a market capitalization of $429.51 million, a PE ratio of 121.58 and a beta of 0.85. Mesa Laboratories, Inc. has a 52 week low of $55.45 and a 52 week high of $131.20.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Tuesday, February 3rd. The medical instruments supplier reported $3.07 EPS for the quarter, topping the consensus estimate of $2.41 by $0.66. The firm had revenue of $65.13 million for the quarter, compared to analyst estimates of $63.23 million. Mesa Laboratories had a net margin of 1.51% and a return on equity of 22.02%. As a group, sell-side analysts anticipate that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Stockholders of record on Saturday, February 28th will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, February 27th. Mesa Laboratories’s dividend payout ratio is 100.00%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on MLAB shares. Weiss Ratings reissued a “sell (d)” rating on shares of Mesa Laboratories in a research note on Thursday, January 22nd. Wall Street Zen raised Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. Wells Fargo & Company upped their price target on Mesa Laboratories from $83.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. Finally, Zacks Research raised Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research note on Friday, January 9th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $94.00.

Institutional Trading of Mesa Laboratories

Several institutional investors and hedge funds have recently made changes to their positions in MLAB. Herald Investment Management Ltd grew its holdings in Mesa Laboratories by 300.0% during the 3rd quarter. Herald Investment Management Ltd now owns 50,000 shares of the medical instruments supplier’s stock valued at $3,340,000 after purchasing an additional 37,500 shares during the last quarter. Diamond Hill Capital Management Inc. increased its position in Mesa Laboratories by 218.0% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 123,381 shares of the medical instruments supplier’s stock valued at $8,268,000 after buying an additional 84,582 shares in the last quarter. Gabelli Funds LLC boosted its stake in shares of Mesa Laboratories by 114.6% during the 3rd quarter. Gabelli Funds LLC now owns 53,974 shares of the medical instruments supplier’s stock worth $3,617,000 after acquiring an additional 28,818 shares in the last quarter. Roubaix Capital LLC acquired a new stake in Mesa Laboratories in the third quarter valued at approximately $5,137,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Mesa Laboratories in the second quarter valued at approximately $452,000. Institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.